Valneva (NASDAQ:VALN) Sees Large Volume Increase - Time to Buy?

Key Points

• Valneva SE experienced a significant increase in trading volume, with approximately 109,053 shares traded on Monday, up 79% from the previous session.
• Analysts have issued mixed ratings on the stock, with HC Wainwright maintaining a "buy" rating with a price target of $17.00, while Guggenheim lowered its target from $15.00 to $14.00.
• An institutional investor, GAMMA Investing LLC, has recently acquired a stake in Valneva, purchasing 13,964 shares valued at around $94,000.

Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) shares saw an uptick in trading volume on Monday . 109,053 shares traded hands during trading, an increase of 79% from the previous session's volume of 60,807 shares.The stock last traded at $8.49 and had previously closed at $9.11.

Wall Street Analysts Forecast Growth

Separately, Guggenheim cut their target price on Valneva from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, May 8th.

Valneva Stock Performance

The company's 50 day moving average price is $6.86 and its 200-day moving average price is $6.75. The stock has a market cap of $981.09 million, a P/E ratio of -11.77 and a beta of 1.77. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.12 and a current ratio of 2.27.

Valneva (NASDAQ:VALN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.11. The firm had revenue of $54.84 million during the quarter, compared to analyst estimates of $46.28 million. Valneva had a negative net margin of 33.87% and a negative return on equity of 34.78%. Equities analysts forecast that Valneva SE Sponsored ADR will post 0.13 EPS for the current fiscal year.

Institutional Investors Weigh In On Valneva

Hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC purchased a new stake in Valneva during the first quarter worth about $94,000. Wells Fargo & Company MN grew its position in shares of Valneva by 14.3% during the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock valued at $1,079,000 after acquiring an additional 30,859 shares during the period. Finally, Frazier Life Sciences Management L.P. purchased a new stake in shares of Valneva during the 2nd quarter worth approximately $8,240,000. 11.39% of the stock is currently owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.